None
Quote | Urovant Sciences Ltd. (NASDAQ:UROV)
Last: | $16.24 |
---|---|
Change Percent: | 0.06% |
Open: | $16.23 |
Close: | $16.24 |
High: | $16.24 |
Low: | $16.21 |
Volume: | 1,739,077 |
Last Trade Date Time: | 03/26/2021 04:57:41 pm |
News | Urovant Sciences Ltd. (NASDAQ:UROV)
Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late breaker presentation by Kenneth M. Peters, M.D. during Friday morning’s plenary session...
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-...
Message Board Posts | Urovant Sciences Ltd. (NASDAQ:UROV)
Subject | By | Source | When |
---|---|---|---|
EOY i believe | Grant Lee | investorshub | 11/16/2020 1:20:36 PM |
When's the FDA approval? | Warrens | investorshub | 11/15/2020 11:49:56 PM |
Wasn't expecting this until after FDA approval, looks | Grant Lee | investorshub | 11/13/2020 2:03:12 PM |
BINGO | Paullee | investorshub | 11/13/2020 1:38:51 PM |
Finally, Sumitomo, a japanese company, owns 75% of | Grant Lee | investorshub | 09/23/2020 6:02:20 PM |
News, Short Squeeze, Breakout and More Instantly...
Urovant Sciences Ltd. Company Name:
UROV Stock Symbol:
NASDAQ Market:
Interim 12-week analysis from a Phase 2a trial of the potential gene therapy, URO-902, in women with overactive bladder (OAB) and urge urinary incontinence (UUI) will be featured in a late breaker presentation by Kenneth M. Peters, M.D. during Friday morning’s plenary session...
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-...
Data from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA ® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urin...